METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New trial tests drug combo for Tough-to-Treat prostate cancer
Disease control OngoingThis study is testing whether combining a targeted radiation drug (lutetium) with a hormone therapy drug (ARPI) works better than the radiation drug alone for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. About 420 partic…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New cancer drug enters human testing for Tough-to-Treat tumors
Disease control OngoingThis study is testing a new drug called NUV-1511 in adults with advanced solid tumors that have stopped responding to standard treatments. The first part checks the drug's safety and finds the right dose, while the second part looks at how well it shrinks tumors in specific cance…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Targeted radiation therapy tested for Tough-to-Treat prostate cancer
Disease control OngoingThis study tested a new type of targeted radiation therapy for Chinese men with advanced prostate cancer that has spread and stopped responding to standard hormone and chemotherapy treatments. The treatment uses a radioactive drug that seeks out and delivers radiation directly to…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Cancer drug safety watch: tracking Long-Term effects
Knowledge-focused ENROLLING_BY_INVITATIONThis study tracks the long-term safety of experimental cancer treatments in patients who previously participated in earlier Janssen trials. It follows 80 people with various cancers to monitor for serious side effects over time. The goal is to better understand the safety profile…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Knowledge-focused
Last updated Mar 11, 2026 14:54 UTC